Clinical Trial Update: The Effect of REcombinant Human Thrombopoietin (rhTPO) on Sepsis Patients With aCUte Severe thrombocytopEnia [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial evaluating recombinant human thrombopoietin (rhTPO) for sepsis patients with acute severe thrombocytopenia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Thrombocytopenia

Drugs mentioned

• recombinant human thrombopoietin (recombinant human thrombopoietin)

Snippet

Sponsor: Ruilan Wang | Conditions: Sepsis, Thrombocytopenia | Phase 2, Phase 3 | Status: RECRUITING